Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Pune is battling a growing health crisis as Guillain-Barre Syndrome (GBS), a rare immunological nerve disorder, has gripped the city. With 101 reported cases and one death, the situation has prompted ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

First death in Maharashtra due to GBS; Pune reports 9 more cases, officials take preventive measures, water contamination ...

In the past six years, Madhya Pradesh has reported 295 JE cases and 10 deaths. The latest victim, a 15-year-old girl from Gwalior, has been hospitalised in critical condition. She suffered from ...

The health officials said that a new Guillain-Barre Syndrome case was reported in Pune on Tuesday; number of suspected GBS ...

Jaipur: The seasonal diseases like Dengue, Malaria and Chikungunya are being reported even in winter in Rajasthan. In the ...